With the Johnson & Johnson (JNJ) COVID vaccine receiving Food and Drug Administration (FDA) emergency authorization for use on Feb. 27, the drugmaker has already begun shipping doses of the vaccine. CEO Alex Gorsky told NBC's "Today" on Monday that the vaccine was "on trucks as we're talking," with Americans expected to begin getting inoculated with the shot within the next day or two. "We're shipping 4 million literally as we speak," Gorsky said. "Within the next 24 to 48 hours, Americans should start receiving shots in arms." Senior Biden Administration officials said on Sunday that healthcare providers will begin receiving the Johnson & Johnson vaccine on Tuesday, with the first 3.9 million doses distributed, CNBC reported.
Johnson & Johnson (JNJ) anticipates that it will sell $2.5 billion in COVID vaccines this year despite concerns that have mounted over the shot since its rollout. The company made the announcement as it released its second-quarter earning report early Wednesday morning. Johnson & Johnson reported a sales growth of 27.1% to $23.2 billion for the quarter with an operational growth of 23% for the quarter with an earnings per share increase of 72.8% to $2.35. Revenue for the company was $22.21 billion. Global sales of the COVID vaccine for the quarter reached $164 million.
Western Kentucky built a 44-30 lead at the half on 17-for-30 shooting including 6 for 11 from 3-point range. Que Johnson had 17 points on near-perfect shooting, going 6 for 7 from the field and hitting all five of his 3-point attempts. Justin Johnson added 12 points on 5-for-7 shooting before intermission.
FILE - In this July 30, 2013, file photo, people walk along a corridor at the headquarters of Johnson & Johnson in New Brunswick, N.J. Amid the storm over soaring medicine prices, health care giant Johnson & Johnson says that beginning in February 2017 the company will disclose average increases in the list price and what middlemen actually pay for its prescription drugs. That will help J&J's image more than patients initially, experts say, but it could push other drugmakers to restrain future price increases and be more transparent.